Latest Headlines

  1. Adagene And ConjugateBio Partner To Develop Novel Antibody Drug Conjugate 7/8/2025

    Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies’ bispecific ADC development programs.

  2. New Drug Targets 'Zombie Cells' In Effort To Prevent Liver Disease, Cancer 7/8/2025

    A new drug candidate developed by Tulane University researchers may work to prevent a common type of fatty liver disease.

  3. Eluciderm, Inc. Announces U.S. FDA Clearance Of IND Application For ELU42 7/8/2025

    Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote healing and regenerative repair of injured tissue, announced today that on June 30, 2025 the company received clearance from the U.S.

  4. Eton Pharmaceuticals Announces FDA Acceptance Of New Drug Application For ET-600 (Desmopressin Oral Solution) 7/8/2025

    Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company’s New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepted for review by the U.S.

  5. Chugai And Gero Enter Into Joint Research And License Agreement To Develop Novel Therapies For Age-Related Diseases 7/7/2025

    Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai"), and Gero PTE. LTD. (hereafter "Gero"), a Singapore-based biotechnology company, announced today that they have entered into a joint research and license agreement to develop novel therapies for age-related diseases.

  6. FF-10832 Granted FDA Orphan Drug Designation For The Treatment Of Biliary Tract Cancer 7/7/2025

    FUJIFILM Pharmaceuticals U.S.A., Inc., drug development center and a leading provider of Contract Development and Manufacturing Organization (CDMO) services for drug delivery system (DDS) technologies, today announced that the U.S.

  7. Research Opens Up New Avenue For Tuberculosis Drug Discovery 7/3/2025

    Researchers investigating the structure and function of the TB enzyme MCR have identified several possible new drug candidates for treating TB.

  8. Forging A Novel Therapeutic Path For Patients With Rett Syndrome Using AI 7/2/2025

    Rett syndrome is a devastating, rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it, and much fewer boys.

  9. Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval For Treatment Of Relapsed Or Refractory Multiple Myeloma 7/2/2025

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody.

  10. Optibrium Partners With TalTech On EU-Funded PhD Programme To Advance Sustainable Drug Discovery 7/2/2025

    Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with TalTech (Tallinn University of Technology) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.